Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer

OBJECTIVES: Immunotherapy by blocking programmed death protein-1 (PD-1) or programmed death protein-ligand1 (PD-L1) with antibodies (PD-1 blockade) has revolutionized treatment options for patients with non-small cell lung cancer (NSCLC). However, the benefit of immunotherapy is limited to a subset...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutta, Nikita, Rohlin, Anna, Eklund, Ella A., Magnusson, Maria K., Nilsson, Frida, Akyürek, Levent M., Torstensson, Per, Sayin, Volkan I., Lundgren, Anna, Hallqvist, Andreas, Raghavan, Sukanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948027/
https://www.ncbi.nlm.nih.gov/pubmed/36844924
http://dx.doi.org/10.3389/fonc.2022.1073457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948027/
https://www.ncbi.nlm.nih.gov/pubmed/36844924
http://dx.doi.org/10.3389/fonc.2022.1073457

Ejemplares similares